bensparham.substack.com
Eli Lilly's Zepbound Takes on Rival Novo Nordisk's Wegovy 💊
In the fast-evolving landscape of pharmaceuticals, Eli Lilly (NYSE:LLY) has entered the arena of weight management with its newly approved medication, Zepbound. A recent report from data analytics firm GlobalData projects that Zepbound could rake in a substantial $4.1 billion in sales by 2031 in the U.S., setting the stage for a heated competition with Novo Nordisk's (NVO) weight loss therapy, Wegovy.